Bildkälla: Stockfoto

Surgical Science Q1 2024: Soft streak continues - Redeye

Redeye updates its estimates following Surgical Science’s Q1 2024 report, which came in considerably below our estimates due to weak Educational Products sales. In contrast, Industry/OEM exceeded our estimates. Despite strong comparables, Educational Products’ weakness surprised us. We lower our estimates for the segment and valuation.

Redeye updates its estimates following Surgical Science’s Q1 2024 report, which came in considerably below our estimates due to weak Educational Products sales. In contrast, Industry/OEM exceeded our estimates. Despite strong comparables, Educational Products’ weakness surprised us. We lower our estimates for the segment and valuation.
Börsvärldens nyhetsbrev
ANNONSER